Quantcast
Home > Quotes > DERM

Dermira, Inc. Common Stock (DERM) Quote & Summary Data

DERM 
$9.93
*  
0.04
0.4%
Get DERM Alerts
*Delayed - data as of Dec. 17, 2018 10:20 ET  -  Find a broker to begin trading DERM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    DERM Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 9.92 / $ 9.94
1 Year Target
18
Today's High / Low
$ 9.95 / $ 9.57
Share Volume
152,071
50 Day Avg. Daily Volume
570,961
Previous Close
$ 9.89
52 Week High / Low
$ 31.42 / $ 6.98
Market Cap
418,260,239
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -4.91
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.04

Intraday Chart

Shares Traded

Share Volume:
152,071
50 Day Avg. Daily Volume:
570,961

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.91

Trading Range

The current last sale of $9.93 is 42.26% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 9.95 $ 31.42
 Low: $ 9.57 $ 6.98

Company Description (as filed with the SEC)

We are a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. We are committed to understanding the needs of both patients and physicians and using our insight to identify and develop leading-edge medical dermatology programs. Our pipeline includes three late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), for which a New Drug Application ("NDA") is under review by the U.S. Food and Drug Administration ("FDA") for the treatment of primary axillary hyperhidrosis (underarm sweating beyond what is needed for normal body temperature regulation); olumacostat glasaretil (formerly DRM01), in Phase 3 development for the treatment of acne vulgaris; and lebrikizumab, in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.  ... More ...  


Risk Grade

Where does DERM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 9.87
Open Date:
Dec. 17, 2018
Close Price:
$ 9.89
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info